| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Yale Cancer Center, Department of Medicine Division of Oncology, New Haven, CT, USA. Electronic address: daniel.petrylak@yale.edu. US Oncology Research, Houston, TX, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russia. Department of Uro-Oncology, Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland. San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, Italy. Texas Oncology, Austin, TX, USA. University Hospital del Mar-IMIM, Barcelona, Spain; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. US Oncology Research, Houston, TX, USA; Rocky Mountain Cancer Centers, Aurora, CO, USA. Catalan Institute of Oncology, Department of Medical Oncology, Barcelona, Spain. Department of Clinical Oncology, The Christie NHS Foundation Trust and Institute of Cancer Sciences, University of Manchester, Manchester, UK. Department of Urology, Rechts der Isar Medical Center, Technische Universitat Munchen, Munchen, Germany. State Institution of Healthcare "Regional Clinical Oncology Dispensary", Omsk, Russia. Centre Leon Berard, Department of Medical Oncology, Lyon, France. Department of Clinical Oncology, Royal Marsden Hospital, London, UK. Medical Oncology Department, Groupe Hospitalier Universitaire Caremeau Place du Professeur Robert Debre, Nimes, France. Celgene Corporation, Summit, NJ, USA. ErasmusMC Cancer Institute, Rotterdam, Netherlands. Institut Gustave Roussy, Department of Cancer Medicine, University of Paris Sud, Villejuif, France. alt-title: The Lancet. Oncology number: 4 accession-num: 25743937 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial |
Institut de Recherche en Cancérologie de
